Solana Co quarterly report, Q3 FY2019

Business context and reporting period

Filing identity: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-Q for the quarter ended September 30, 2019, not a filing for “Solana Co.” Investors should verify that this is the intended issuer. Financial amounts below are in U.S. dollars; statement amounts are in thousands unless stated otherwise. The financial statements are unaudited.

Helius develops neurotechnology products. Its PoNS device was authorized for sale in Canada for a limited treatment of chronic balance deficit following mild-to-moderate traumatic brain injury (mmTBI), but was investigational in the U.S., EU and Australia. The company had begun commercial sales in Canada.

Financial results and liquidity

Q3 gross margin was approximately 41% of revenue; nine-month gross margin was approximately 60%. These ratios include reported gross profit divided by total revenue.

At September 30, cash was $9.019 million, current assets were $11.228 million and current liabilities were $3.547 million, including $83,000 of derivative liabilities. Working capital, excluding derivative financial instruments as the company defines it, was $7.764 million. Total liabilities were $4.058 million, including $675,000 of operating lease liabilities. The filing reports no conventional borrowings in the balance sheet.

Cash declined $16.564 million during the first nine months. Investing activities used $260,000; financing activities provided $163,000. Stockholders’ equity was $8.822 million and accumulated deficit was $99.442 million.

Material changes versus comparable periods

• Commercial PoNS product revenue began in Canada: Q3 revenue was $150,000, and nine-month revenue was $1.295 million from product sales plus $49,000 in fee revenue. Comparable 2018 periods had no revenue.
• Q3 operating loss increased by $846,000 year over year, as SG&A rose $1.710 million, partly offset by $803,000 lower R&D. SG&A included higher stock-based compensation, severance and commercial-launch staffing costs.
• Nine-month operating loss improved by $3.042 million, reflecting lower operating expenses. R&D fell $1.319 million, primarily as device development costs declined; SG&A fell $917,000 overall despite higher commercial spending.
• Nine-month net loss improved by $19.058 million, principally because of a $14.033 million non-cash gain from changes in derivative fair value, compared with a $3.356 million loss in 2018. This gain should not be read as operating improvement or cash generation.
• Cash fell from $25.583 million at year-end 2018 to $9.019 million. The company had no significant financing proceeds in the 2019 nine-month period, versus $18.4 million of offering proceeds in the comparable 2018 period.
• Derivative liabilities declined from $13.769 million at December 31, 2018 to $83,000 at September 30, 2019, substantially affecting reported earnings through fair-value changes.

Outlook, risks, contingencies and unusual items

• Funding and going concern: Management stated that existing capital resources were expected to fund operations only into the first quarter of 2020. The filing says substantial doubt exists about the company’s ability to continue as a going concern within one year after filing. Additional capital may be unavailable or costly; the company warned it could reduce operations, sell assets or cease operations.
• Regulatory path: The FDA denied the PoNS de novo request in April 2019, citing insufficient evidence to separate the device’s contribution from physical therapy. Following an October 2019 pre-submission meeting, management estimated a new de novo request could be submitted in Q3 2020 after a new study. This is an estimate, not a guarantee. The EU application was withdrawn amid regulatory transition and notified-body uncertainty. Australia’s application was under review.
• Canadian commercialization: Management described early patient outcomes and adherence as encouraging, while noting new clinics would need time to become operational. It reported full reimbursement for two patients and was developing reimbursement processes. These are early results and do not establish sustained demand or reimbursement coverage.
• Business restructuring and acquisition: Following the FDA denial, the company reduced its workforce by more than 30% and shifted resources toward U.S. resubmission and Canadian commercialization. On October 30, 2019, it acquired Heuro from HTC for approximately $1.6 million in stated total consideration, which included devices, a receivable and other items; the filing does not state that the entire amount was a cash payment. A related co-promotion agreement included a 10-year regional exclusivity right for HTC, renewable for another 10 years.
• Litigation: Two putative shareholder class actions allege misleading statements regarding FDA approval prospects. The company said it intends to defend the cases but could not predict outcomes.
• Cyber-fraud and controls: A business-email-compromise incident in October 2019 resulted in an approximately $100,000 wire transfer; no funds had been recovered as of the filing. Management identified a material weakness in vendor wire-payment verification and concluded disclosure controls were not effective at period-end. It described payment-control enhancements but gave no assurance remediation would be effective.
• Other commitments and exposures: The company disclosed approximately $300,000 of commitments to its device manufacturer, a 4% royalty on qualifying net revenue, and lease obligations of $675,000. It reported foreign-exchange exposure and no hedging. The U.S. Army-related $2 million contractual penalty was considered remote after the obligation was amended and met.
• No formal financial guidance: The filing provides no quantified revenue or earnings guidance; management’s key timing estimate is the potential Q3 2020 FDA resubmission.

Most important facts for investors to verify

• Confirm the issuer: the source is Helius Medical Technologies, Inc. (ticker HSDT), not Solana Co.
• Verify current cash runway, subsequent financing and actual operating cash burn against the stated expectation that resources would last into Q1 2020.
• Track the design, enrollment, results and timing of the FDA-required study and whether the planned Q3 2020 submission occurred.
• Assess Canadian device sales, clinic utilization, patient outcomes and the durability of reimbursement beyond the two reported cases.
• Review the Heuro acquisition accounting, consideration details, subsequent commercial performance and HTC exclusivity terms.
• Monitor the shareholder litigation, recovery of the $100,000 fraud loss and evidence that the identified control weakness has been remediated.